Media-OutReach Newswire AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval
Media-OutReach Newswire Acquisition of Three High-Quality Assets Drive Diversified Business Development for Goldstream Investment
Media-OutReach Newswire Phase III clinical data of AIM Vaccine iterative serum-free rabies vaccine reaches preset goals
Politics & Law Vietnamese leader visits Ireland's National Institute for Bioprocessing Research & Training
Media-OutReach Newswire The bull market of innovative drug technology is booming, and the leading stock AIM Vaccine has erupted upward